AKT1 and Alzheimer disease: We highlighted the role of TLRs, TNF and IL4 to trigger the anti-inflammatory response and AKT1-PKN2 and TGFA via MAPK cascade to affect the skin barrier proteins in AD patients, when treated with BM.